J B Hunt Transport Services Inc vs Neurocrine Biosciences Inc — how do they compare? J B Hunt Transport Services Inc trades at $267 (market cap $24.92B), while Neurocrine Biosciences Inc trades at $154.4 (market cap $16.46B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| JBHT | NBIX | |
|---|---|---|
Market Cap | $24.92B | $16.46B |
Sector | Industrials | Health |
52-Week High | $298.41 | $185.50 |
52-Week Low | $130.65 | $123.10 |
Enterprise Value | $26.06B | $16.48B |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
JBHT stock trades at $266.14, down 0.89% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue trends show stabilization after a decline from 2022 peaks, while profitability metrics like ROE at 18.45% and net margin at 5.31% reflect efficient operations. Recent news highlights the company's 65th anniversary and partnerships to enhance freight technology.
The outlook is positive with a consensus price target of $299.82, implying 12.6% upside, supported by analyst buy ratings (57.78%). Risks include economic sensitivity impacting freight demand and competitive pressures. Earnings execution and intermodal demand recovery are key catalysts for stock appreciation.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →